Research highlights from the 2021 SUO Annual Meeting
“The SUO has never been stronger in its ability to deliver on clinical trials,” says Michael S. Cookson, MD, MMHC, FACS.
In this video, the Society of Urologic Oncology’s (SUO) Past President Michael S. Cookson, MD, MMHC, FACS, discusses the main highlights from this year’s annual meeting, including trials and topics from the prostate and bladder cancer spaces. Cookson is a professor and the Donald D. Albers endowed chair in urology at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
November 30th 2023Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.
